Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Excretion Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.

NCT00661765
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline tartrate, varenicline free base
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2009 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Addition of Phytosterols to a Low Phytosterol Diet

NCT00860054
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Different amount of phytosterols are added into diets
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity

NCT01065571
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
carrageenan, dietary intervention with no-carrageenan diet
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants

NCT06901336
View directory record Official record
Conditions
Healthy
Interventions
[14C]-STX-478
Drug
Lead sponsor
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

NCT06088264
View directory record Official record
Conditions
Healthy Male Participants
Interventions
BMS-986322
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 19, 2026, 8:14 PM EDT
Terminated Not applicable Interventional

Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus

NCT00386594
View directory record Official record
Conditions
Barrett Esophagus
Interventions
852A
Drug
Lead sponsor
Rogers, B.H. Gerald, M.D.
Individual
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 19, 2026, 8:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

NCT02521285
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

NCT01359605
View directory record Official record
Conditions
Healthy Volunteers
Interventions
varespladib methyl
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 20, 2011 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 1Phase 2 Interventional

An Autism Study Using Nambudripad's Food Allergy Elimination Treatments

NCT00247156
View directory record Official record
Conditions
Autism, Food Allergies
Interventions
Acupressure treatments and NAET treatments
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
3 Years to 10 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2008 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids

NCT02610816
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastrointestinal Disorders (EGIDs)
Interventions
1 Food Elimination Diet, 4 Food Elimination Diet, 4 Food Elimination Diet (post 1FED failure), Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
Other · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants

NCT06049108
View directory record Official record
Conditions
Healthy
Interventions
[14C]-LY3871801
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

NCT02772159
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TD-4208
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 19, 2026, 8:14 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Drug Excretion in Breast Milk

NCT06056583
View directory record Official record
Conditions
Postpartum, Lactation, Drugs in Breast Milk, Mammary Drug Transporters, BCRP, OCT1
Interventions
Cimetidine 200 MG
Drug
Lead sponsor
University of Washington
Other
Eligibility
14 Days to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Flavanol Absorption, Metabolism and Excretion From Fruit-based Drinks and Other Food Matrixes

NCT03526094
View directory record Official record
Conditions
Healthy
Interventions
Flavanols-capsules, Flavanol-banana blend, Flavanol-high protein drink, Flavanol-berry blend, Flavanol-sports drink, Flavanol-peanut butter toast, Flavanol-oats, Flavanol-yogurt, II- Flavanol drink, II- Flavanol drink + banana blend
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 19, 2026, 8:14 PM EDT
Withdrawn Not applicable Interventional

Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms

NCT02758002
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmia
Interventions
Firm ablation for transitional AF rotors
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine

NCT00800956
View directory record Official record
Conditions
Healthy
Interventions
[14C]-esreboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 65 Years · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

NCT04415645
View directory record Official record
Conditions
Healthy Adult Male
Interventions
[14C]-VVZ-149
Drug
Lead sponsor
Vivozon, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 19, 2026, 8:14 PM EDT
Completed No phase listed Observational

Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

NCT05611905
View directory record Official record
Conditions
Renal Excretion, Bacterial Infections, Inflammatory Disease, Oncologic Disease
Interventions
11C-para-aminobenzoic acid PET/CT, Probenecid
Combination Product · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease

NCT01684722
View directory record Official record
Conditions
Diabetes
Interventions
Vitamin D, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects

NCT02497924
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

NCT01544491
View directory record Official record
Conditions
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Interventions
RAD001, MMF
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 19, 2026, 8:14 PM EDT
Withdrawn Not applicable Interventional

Short Duration 6Fed Sponge For EoE Patients

NCT03354221
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cytosponge, Diet, EEsAI Pro, Likert Scoring Scale
Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 19, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

NCT01801293
View directory record Official record
Conditions
RSV Infection
Interventions
GS-5806
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 19, 2026, 8:14 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT05650112
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
FB-001, Placebo
Biological
Lead sponsor
Federation Bio Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 19, 2026, 8:14 PM EDT